ANVS News and Press, Annovis Bio Inc.

A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...

2024-07-02 14:30:51 ET More on Annovis Bio Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects ...

Annovis Bio (NYSE: ANVS) , a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD s...

Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.  Parkinson’s patients with substantial cognitive decline exhibited a very pronounced improvement. Buntanetap showed statistical improvement in the ...

2024-06-30 11:48:25 ET Summary Annovis Bio's only potential catalyst is the upcoming Phase 3 readout for Parkinson's disease. The company's changes to the primary endpoints of that trial, contrary to the FDA's wishes, cause concern. There is now more certainty that the Phase 2...

Buntanetap is designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43 The study demonstrated significant efficacy and safety for buntanetap in a subgroup of early Alzheimer’s patients in bot...

2024-06-27 08:39:20 ET More on Annovis Bio Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap ...

MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS ) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheim...

Annovis Bio (NYSE: ANVS) , a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed a patent with the U.S. Patent and...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disea...